PMID- 23296071
OWN - NLM
STAT- MEDLINE
DCOM- 20130604
LR  - 20211021
IS  - 1759-5010 (Electronic)
IS  - 1759-5002 (Linking)
VI  - 10
IP  - 2
DP  - 2013 Feb
TI  - Cardiovascular effects of gliptins.
PG  - 73-84
LID - 10.1038/nrcardio.2012.183 [doi]
AB  - Dipeptidyl peptidase 4 (DPP-4) inhibitors (commonly referred to as gliptins) are 
      a novel class of oral antihyperglycaemic agents with demonstrated efficacy in the 
      treatment of type 2 diabetes mellitus (T2DM). Preclinical data and mechanistic 
      studies have indicated a possible beneficial action on blood vessels and the 
      heart, via both glucagon-like peptide 1 (GLP-1)-dependent and GLP-1-independent 
      effects. DPP-4 inhibition increases the concentration of many peptides with 
      potential vasoactive and cardioprotective effects. Clinically, DPP-4 inhibitors 
      improve several risk factors in patients with T2DM. They improve blood glucose 
      control (mainly by reducing postprandial glycaemia), are weight neutral (or even 
      induce modest weight loss), lower blood pressure, improve postprandial lipaemia, 
      reduce inflammatory markers, diminish oxidative stress, and improve endothelial 
      function. Some positive effects on the heart have also been described in patients 
      with ischaemic heart disease or congestive heart failure, although their clinical 
      relevance requires further investigation. Post-hoc analyses of phase II-III, 
      controlled trials suggest a possible cardioprotective effect with a trend for a 
      lower incidence of major cardiovascular events with gliptins than with placebo or 
      active agents. However, the actual relationship between DPP-4 inhibition and 
      cardiovascular outcomes remains to be proven. Major prospective clinical trials 
      with predefined cardiovascular outcomes and involving various DPP-4 inhibitors 
      are now underway in patients with T2DM and a high-risk cardiovascular profile.
FAU - Scheen, Andre J
AU  - Scheen AJ
AD  - Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, 
      CHU Sart Tilman (B35), University of Liege, B-4000 Liege 1, Belgium. 
      andre.scheen@chu.ulg.ac.be
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130108
PL  - England
TA  - Nat Rev Cardiol
JT  - Nature reviews. Cardiology
JID - 101500075
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipids)
SB  - IM
MH  - Animals
MH  - Biomarkers/blood
MH  - Blood Glucose/drug effects/metabolism
MH  - Blood Pressure/drug effects
MH  - Cardiovascular Agents/*therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/*drug 
      therapy/enzymology/mortality/physiopathology
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Endothelium, Vascular/drug effects/physiopathology
MH  - Heart Failure/*drug therapy/enzymology/mortality/physiopathology
MH  - Humans
MH  - Inflammation Mediators/blood
MH  - Lipids/blood
MH  - Myocardial Ischemia/blood/*drug therapy/enzymology/mortality/physiopathology
MH  - Oxidative Stress/drug effects
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2013/01/09 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/01/09 06:00
PHST- 2013/01/09 06:00 [entrez]
PHST- 2013/01/09 06:00 [pubmed]
PHST- 2013/06/05 06:00 [medline]
AID - nrcardio.2012.183 [pii]
AID - 10.1038/nrcardio.2012.183 [doi]
PST - ppublish
SO  - Nat Rev Cardiol. 2013 Feb;10(2):73-84. doi: 10.1038/nrcardio.2012.183. Epub 2013 
      Jan 8.